About Ablexis
Ablexis is a company based in San Francisco (United States) founded in 2009 was acquired by Deerfield in June 2018. Ablexis has raised $12 million across 1 funding round from investors including Third Rock Ventures, Pfizer Venture Investments and Deerfield. Ablexis offers products and services including Transgenic Mouse Platform. Ablexis operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ablexis, Llc
- Jurisdiction Bangalore North, Karnataka, India
-
Annual Revenue
$403.09 K (USD)19.31as on Mar 31, 2022
-
Net Profit
$26.11 K (USD)-14.87as on Mar 31, 2022
-
EBITDA
$31.2 K (USD)28.43as on Mar 31, 2022
-
Total Equity Funding
$12 M (USD)
in 1 rounds
-
Latest Funding Round
$12 M (USD), Series A
Jun 02, 2010
-
Investors
Third Rock Ventures
& 2 more
-
Employee Count
Not available
-
Acquired by
Deerfield
(Jun 21, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ablexis
Ablexis offers a comprehensive portfolio of products and services, including Transgenic Mouse Platform.
Platform for discovering and developing therapeutic antibody candidates efficiently.
People of Ablexis
Unlock access to complete
Unlock access to complete
Funding Insights of Ablexis
Ablexis has successfully raised a total of $12M through 1 strategic funding round. The most recent funding activity was a Series A round of $12 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ablexis
Ablexis has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Third Rock Ventures, Pfizer Venture Investments and Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked | |
|
Venture capital is focused on healthcare by Pfizer's investment arm.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked |
Investor details for Ablexis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ablexis
Investment portfolio details for Ablexis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ablexis
Detailed financials for Ablexis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ablexis Comparisons
Peer comparison for Ablexis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ablexis
Ablexis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Ablexis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ablexis
Complete news archive for Ablexis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ablexis
Ablexis was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Ablexis is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Ablexis is a funded company, having raised a total of $12M across 1 funding round to date.
Annual revenue of Ablexis is $403.09K as on Mar 31, 2022.
Ablexis was founded in 2009 in San Francisco, United States, within the biotechnology sector focused on antibody development. Transgenic mouse platforms are created by the company to support human antibody drug discovery and development. The AlivaMab Mouse platform was acquired from Aliva Biopharmaceuticals, featuring immunoglobulin loci designed for efficient function in these processes. In 2010, a consortium was formed, licensing the technology to five leading global biopharmaceutical firms, including Pfizer.
Ablexis's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Ablexis offers Transgenic Mouse Platform.
Ablexis has 3 investors. Key investors include Third Rock Ventures, Pfizer Venture Investments, and Deerfield.